NEW YORK (GenomeWeb News) – HistoRx today said that it has licensed from Yale University a new melanoma assay based on the Aqua technology invented at Yale.
Branford, Conn.-based HistoRx said the licensed assay will enable physicians to identify a subset of patients who despite having no detectable cancer in their lymph nodes have a 40 percent risk of recurrence of their disease. The prognostic assay was developed by David Rimm, inventor of the underlying Aqua technology and the director of pathology tissue services at the Yale School of Medicine.
The Aqua technology is an automated, quantitative immunohistochemistry testing method that enables measurement of protein biomarkers in tissue.
The test contains five biomarkers and provides results intended to delineate between low-risk and high-risk patients.
HistoRx said the test also may be useful in guiding treatment decisions for Stage II, node-negative melanoma patients.
Terms of the licensing agreement were not disclosed.